Axonics Modulation Technologies (AXNX)

Axonics Modulation Technologies Stock Analysis & Ratings



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Axonics Modulation Technologies’s price range in the past 12 months?
Axonics Modulation Technologies lowest stock price was $38.41 and its highest was $79.81 in the past 12 months.
    What is Axonics Modulation Technologies’s market cap?
    Currently, no data Available
    What is Axonics Modulation Technologies’s price target?
    The average price target for Axonics Modulation Technologies is $81.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $87.00 ,the lowest forecast is $75.00. The average price target represents 15.58% Increase from the current price of $70.08.
      What do analysts say about Axonics Modulation Technologies?
      Axonics Modulation Technologies’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
        When is Axonics Modulation Technologies’s upcoming earnings report date?
        Axonics Modulation Technologies’s upcoming earnings report date is Dec 13, 2022 which is in 123 days.
          How were Axonics Modulation Technologies’s earnings last quarter?
          Axonics Modulation Technologies released its earnings results on Aug 01, 2022. The company reported -$0.47 earnings per share for the quarter, beating the consensus estimate of -$0.549 by $0.079.
            Is Axonics Modulation Technologies overvalued?
            According to Wall Street analysts Axonics Modulation Technologies’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Axonics Modulation Technologies pay dividends?
              Axonics Modulation Technologies does not currently pay dividends.
              What is Axonics Modulation Technologies’s EPS estimate?
              Axonics Modulation Technologies’s EPS estimate is -$0.47.
                How many shares outstanding does Axonics Modulation Technologies have?
                Axonics Modulation Technologies has 48,867,718 shares outstanding.
                  What happened to Axonics Modulation Technologies’s price movement after its last earnings report?
                  Axonics Modulation Technologies reported an EPS of -$0.47 in its last earnings report, beating expectations of -$0.549. Following the earnings report the stock price went up 6.781%.
                    Which hedge fund is a major shareholder of Axonics Modulation Technologies?
                    Among the largest hedge funds holding Axonics Modulation Technologies’s share is Perceptive Advisors LLC. It holds Axonics Modulation Technologies’s shares valued at 21M.


                      Axonics Modulation Technologies Stock Analysis

                      Smart Score
                      Price Target
                      ▲(15.58% Upside)
                      Strong Buy
                      The Axonics Modulation Technologies stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Axonics Modulation Technologies

                      Axonics Modulation Technologies, Inc. operates as a medical technology company, which engages in the design, development, and commercialization of sacral neuromodulation solutions. The firm focuses on the treatment of patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). It offers rechargeable SNM system, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. The company was founded by Guang Qiang Jiang, Danny L. Dearen, Timothy Deer, and Michael V. Williamson in March 2012 and is headquartered in Irvine, CA.

                      Similar Stocks
                      Price & Change
                      Abbott Labs
                      Intuitive Surgical
                      Becton Dickinson
                      Edwards Lifesciences

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis